Drugs / NL005
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT05984134 | Jul 2022 → May 2023 | acute myocardial infarction | Beijing Northland Biotech. Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NL005 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05984134 ↗ |
| Known as | Recombinant Human Thymosin β4 | “Efficacy and Safety of Recombinant Human Thymosin β4(NL005) for Injection in Patients With Acute Myocardial Infarction: a Phase IIb Clinical Study” NCT05984134 ↗ |
| Modality | Protein / enzyme biologic | “Recombinant Human Thymosin β4” NCT05984134 ↗ |
| Route | Intravenous | “intravenous injection” NCT05984134 ↗ |